Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387477450> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W4387477450 endingPage "30" @default.
- W4387477450 startingPage "29" @default.
- W4387477450 abstract "Introduction Withdrawn in the early 2000s, aprotinin marketing authorization was reinstated by European Medicines Agency with a restrictive indication (isolated coronary artery bypass graft surgery, iCABG) and a safety registry (NAPaR) (1). This regsitry intended to record the pattern of use of aprotinin and to determine patient safety. It was terminated without safety signals associated with the product (2). Two aprotinin regimens were allowed: full-dose (FD) and half-dose (HD). Our objective was to compare efficacy and safety of each regimen in patients undergoing cardiac surgery with cardiopulmonary bypass. Methods Between February 2016 and August 2022, 6730 adult patients were treated with aprotinin across 9 European countries (Germany, Austria, Belgium, France, Ireland, Norway, United Kingdom and Sweden) and were included in the registry Results Among the 1549 patients treated on-label (iCABG), 643 (42%) received the FD regimen and 906 (58%) the HD. Less thromboembolic events (0,5% vs 2,8%; P<0,001) and fibrinogen transfusion, but more platelets and cryoprecipitate were reported in the FD group (Table) . Among the 5181 patients treated off-label (ascending aorta surgery, single or complex valves replacement, transplant), 2318 (45%) received the FD and 2863 (55%) the HD. Less mortality (5,4% vs 9,4%; P<0,001), thromboembolic events (1,4% vs 2,9%; P<0,001), renal events (14,8% vs 18,1%; P=0,002), reoperation for bleeding (5,2% vs 10,3%; P<0,001) and fibrinogen transfusion were reported in the FD group, in association with a rise in transfusion needs (platelets and cryoprecipitate). Discussion Regardless of the surgery, the FD of aprotinin, in comparison with the HD regimen, was associated with less postoperative TEE. Concerning aprotinin use in off-label high bleeding risk surgery, FD regimen was also associated with a decrease in postoperative mortality, reoperation for bleeding and renal dysfunction. To confirm these results, a multivariate analysis will be carried out on propensity-matched sets of HD and FD treated subjects. A large multicenter randomized trial is expected to consolidate the potential benefits of routine use of FD aprotinin in cardiac surgery patients." @default.
- W4387477450 created "2023-10-11" @default.
- W4387477450 creator A5013698146 @default.
- W4387477450 creator A5015863687 @default.
- W4387477450 creator A5031723142 @default.
- W4387477450 creator A5034264651 @default.
- W4387477450 creator A5041256702 @default.
- W4387477450 creator A5045866570 @default.
- W4387477450 creator A5067341550 @default.
- W4387477450 creator A5068117695 @default.
- W4387477450 creator A5071434798 @default.
- W4387477450 date "2023-10-01" @default.
- W4387477450 modified "2023-10-16" @default.
- W4387477450 title "NAPAR: EFFICACY AND SAFETY OF APROTININ IN CARDIAC SURGERY: COMPARISON BETWEEN DOSE REGIMEN" @default.
- W4387477450 doi "https://doi.org/10.1053/j.jvca.2023.08.067" @default.
- W4387477450 hasPublicationYear "2023" @default.
- W4387477450 type Work @default.
- W4387477450 citedByCount "0" @default.
- W4387477450 crossrefType "journal-article" @default.
- W4387477450 hasAuthorship W4387477450A5013698146 @default.
- W4387477450 hasAuthorship W4387477450A5015863687 @default.
- W4387477450 hasAuthorship W4387477450A5031723142 @default.
- W4387477450 hasAuthorship W4387477450A5034264651 @default.
- W4387477450 hasAuthorship W4387477450A5041256702 @default.
- W4387477450 hasAuthorship W4387477450A5045866570 @default.
- W4387477450 hasAuthorship W4387477450A5067341550 @default.
- W4387477450 hasAuthorship W4387477450A5068117695 @default.
- W4387477450 hasAuthorship W4387477450A5071434798 @default.
- W4387477450 hasConcept C126322002 @default.
- W4387477450 hasConcept C141071460 @default.
- W4387477450 hasConcept C2776689292 @default.
- W4387477450 hasConcept C2778249958 @default.
- W4387477450 hasConcept C2778258694 @default.
- W4387477450 hasConcept C2778789114 @default.
- W4387477450 hasConcept C2778881276 @default.
- W4387477450 hasConcept C2779036427 @default.
- W4387477450 hasConcept C2779980429 @default.
- W4387477450 hasConcept C2780014101 @default.
- W4387477450 hasConcept C2780799893 @default.
- W4387477450 hasConcept C2781413609 @default.
- W4387477450 hasConcept C42219234 @default.
- W4387477450 hasConcept C71924100 @default.
- W4387477450 hasConcept C89560881 @default.
- W4387477450 hasConceptScore W4387477450C126322002 @default.
- W4387477450 hasConceptScore W4387477450C141071460 @default.
- W4387477450 hasConceptScore W4387477450C2776689292 @default.
- W4387477450 hasConceptScore W4387477450C2778249958 @default.
- W4387477450 hasConceptScore W4387477450C2778258694 @default.
- W4387477450 hasConceptScore W4387477450C2778789114 @default.
- W4387477450 hasConceptScore W4387477450C2778881276 @default.
- W4387477450 hasConceptScore W4387477450C2779036427 @default.
- W4387477450 hasConceptScore W4387477450C2779980429 @default.
- W4387477450 hasConceptScore W4387477450C2780014101 @default.
- W4387477450 hasConceptScore W4387477450C2780799893 @default.
- W4387477450 hasConceptScore W4387477450C2781413609 @default.
- W4387477450 hasConceptScore W4387477450C42219234 @default.
- W4387477450 hasConceptScore W4387477450C71924100 @default.
- W4387477450 hasConceptScore W4387477450C89560881 @default.
- W4387477450 hasLocation W43874774501 @default.
- W4387477450 hasOpenAccess W4387477450 @default.
- W4387477450 hasPrimaryLocation W43874774501 @default.
- W4387477450 hasRelatedWork W2000629406 @default.
- W4387477450 hasRelatedWork W2011667032 @default.
- W4387477450 hasRelatedWork W2073889730 @default.
- W4387477450 hasRelatedWork W2118597154 @default.
- W4387477450 hasRelatedWork W2376477982 @default.
- W4387477450 hasRelatedWork W2378802992 @default.
- W4387477450 hasRelatedWork W2390763401 @default.
- W4387477450 hasRelatedWork W2391524328 @default.
- W4387477450 hasRelatedWork W2405821031 @default.
- W4387477450 hasRelatedWork W2414531805 @default.
- W4387477450 hasVolume "37" @default.
- W4387477450 isParatext "false" @default.
- W4387477450 isRetracted "false" @default.
- W4387477450 workType "article" @default.